Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

Glaxo expects strong growth in year

Article Abstract:

Glaxo Wellcome PLC is implementing new marketing projects and awaiting the launch of several new drugs. This is according to Glaxo's chairman, Sir Richard Sykes. The company's new drugs will bring about strong and consistent growth for the next few years. Mr. Sykes would not be more specific as to how much growth he expected for Glaxo. The company posted disappointing results for the first-half of 1999.

Comment:

Implementing new marketing projects and awaiting launch of several new drugs

Author: Winslow, Ron
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
United Kingdom, Strategy & planning, Management, Abstract, Glaxo Wellcome PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Heart drugs' success poses hurdles for their makers

Article Abstract:

Cardiovascular medications and therapies have become so advanced that is difficult for researchers to improve on current products. "It is going to be very tough to find new therapies with incremental benefit" says Steven Nissen, a cardiologist and researcher. Cardiovascular agents generate $86 billion in annual revenue or 17 percent of global pharmaceutical sales.

Author: Winslow, Ron
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2005
Forecasts, trends, outlooks, Science & research, Cardiovascular Preparations, Research, International aspects, Cardiovascular agents, Industry forecasts

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Drug maker Cor upstages giants by undercutting

Article Abstract:

COR Thereapeutics, a small drug company produces a blood clot inhibitor called Integrillin which has taken the market share from the leaders in the field, Eli Lilly and Johnson and Johnson. At $450 a dose it is much cheaper than its competitors.

Author: Winslow, Ron
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
Market share, Consumer prices, Blood Clot Dissolvers, Statistical Data Included, Statistics, Eli Lilly and Co., Johnson & Johnson, LLY, Fibrinolytic agents, JNJ, COR Therapeutics Inc., CORR

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, Drugs, United States
Similar abstracts:
  • Abstracts: Web entrepreneurs change how China does business. Amazon hopes for happy holidays. Softlock powered e-book sensation, then reality set in
  • Abstracts: LVMH expects profit growth to top 20%. LVMH's sales grew 35% in 2000
  • Abstracts: Daimler, GM discuss sharing SUV costs. BT plan to let web services offer flat rate. Former World Online chief wants to help small investors
  • Abstracts: Allianz to buy venture stakes in Taiwan pair. Holzmann union lengthens workweek. Allianz gets started on major shuffle of industrial assets
  • Abstracts: UniCredito board to discuss plans for expansion. Italy tells Mediobanca, SAI to make full bid for Fondiaria. Two banks in North Italy plan merger
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.